^
Association details:
Biomarker:EGFR L858R
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations

Published date:
05/05/2023
Excerpt:
85 NSCLC patients with EGFR mutations, enrolled at the Zhejiang Cancer Hospital, received ICI combinations after resistance to prior EGFR-tyrosine kinase inhibitors (EGFR-TKIs)….Patients with L858R mutations had a longer PFS and OS than patients with exon 19 deletions.
DOI:
https://doi.org/10.1186/s12890-023-02466-9
Evidence Level:
Sensitive: C3 – Early Trials
Title:

The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study

Published date:
09/09/2022
Excerpt:
CONTRADICTING EVIDENCE: Primary EGFR mutation type and treatment mode were found to have a notable impact on clinical outcomes. Both median PFS and OS in patients with EGFR L858R mutation were significantly shorter than those in patients with EGFR exon 19 deletion (19del) (PFS: 2.5 versus 6.7 months, HR: 1.80, log-rank P=0.011; OS: 9.8 versus 26.9 months, HR: 2.48, log-rank P=0.002)....Our study suggests that ICI-based combination therapy is a potential strategy for EGFR-mutated NSCLC patients after EGFR-TKI failure. The efficacy may differ according to EGFR subtypes.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.3389/fimmu.2022.975
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study

Published date:
01/04/2022
Excerpt:
In total, 309 non-squamous NSCLC patients with a median age of 61 years (range 20-88 years) including 70.9% male were retrospectively enrolled….ICI combined therapy was significantly correlated with a longer PFS compared with ICI monotherapy (median PFS: 7.7 months vs. 4.7 months; P = 0.0112) [Figure 4C]. PFS was 5.5 months in L858R, 5.9 months in 19del, and 9.0 months in Exon20 insertion and other mutations....ICI-based combination therapy can bring benefit to patients with EGFR-mutant NSCLC.
Secondary therapy:
Chemotherapy
DOI:
10.20517/cdr.2021.85
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer

Published date:
12/13/2021
Excerpt:
We collected data for patients with EGFR-mutated NSCLC receiving monotherapy with ICIs…The survival of patients with L858R tumors was significantly longer than that of patients with exon 19 deletion (HR: 0.35, 95% CI: 0.13-0.93, p = 0.026).
DOI:
10.1111/1759-7714.14267
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation

Published date:
11/23/2021
Excerpt:
Relevant clinical data of EGFR-mutant NSCLC patients who had received ICIs were collected from multiple hospitals….A high PD-L1 expression (tumor proportion score, TPS≥50%) and the EGFR L858R mutation were only significantly associated with a better PFS (P <0.05).
DOI:
10.3389/fonc.2021.739090